AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3542325 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide hydrochloride (10 mg)
Number of subjects: 115
Study 30968534 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicines (CHMs)
Number of subjects: 6609
Study 30968534 — intervention group
Group type: COMPARATOR
Intervention: Non-Chinese herbal medicine users (controls)
Number of subjects: 6609
Study 30968534 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicines (CHMs) for over 2 years
Number of subjects: 6609
Study 28444574 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (six home visits)
Number of subjects: 130
Study 28444574 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 130
Study 27373452 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral transvenous phrenic nerve stimulation (remede(R) System)
Number of subjects: 47
Study 24835503 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-β1
Number of subjects: 0
Study 24835503 — intervention group
Group type: EXPERIMENTAL
Intervention: PLN inhibition
Number of subjects: 0
Study 24835503 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 23134887 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation (vitamin B complex and vitamins C and E)
Number of subjects: 2387
Study 23134887 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation (vitamin B complex and vitamins C and E) among children whose mothers received ARV therapy
Number of subjects: 2387
Study 23134887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2387
Study 20504786 — intervention group
Group type: EXPERIMENTAL
Intervention: MIRROR
Number of subjects: 34
Study 20504786 — intervention group
Group type: COMPARATOR
Intervention: DIRECT
Number of subjects: 34
Study 18822796 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic suggestions of analgesia during different conditions (pre-hypnosis, neutral hypnosis, suggestions for analgesia, posthypnotic conditions)
Number of subjects: 0
Study 18822796 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestions for analgesia administered after a mental stress instead of neutral hypnosis
Number of subjects: 0
Study 18822796 — intervention group
Group type: COMPARATOR
Intervention: Hypnotic relaxation and suggestions of analgesia in healthy Lows receiving nociceptive stimulation
Number of subjects: 0
Study 16040874 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma clubs intervention (weekly sessions over 8 weeks)
Number of subjects: 173
Study 16040874 — intervention group
Group type: COMPARATOR
Intervention: Delayed group (control)
Number of subjects: 173
Study 11778093 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine (group R, n=22)
Number of subjects: 66
Study 11778093 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine (group L, n=22)
Number of subjects: 66
Study 11778093 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (group B, n=22)
Number of subjects: 66
Study 9569656 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention focused on self with personal failure
Number of subjects: 0
Study 9569656 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention focused on experimenter with personal failure
Number of subjects: 0
Study 9569656 — intervention group
Group type: COMPARATOR
Intervention: Attention focused on self or experimenter with universal failure
Number of subjects: 0
Study 7819687 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal douche with chlorhexidine solution (method I)
Number of subjects: 2853
Study 7819687 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine gluconate obstetrical gel during vaginal exploration (method II)
Number of subjects: 2853
Study 3047334 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol plus dexamethasone
Number of subjects: 0
Study 3047334 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine plus dexamethasone
Number of subjects: 0
Study 1357913 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% apraclonidine
Number of subjects: 40
Study 1357913 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 40
Study 635479 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 16
Study 635479 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin
Number of subjects: 16
Study 31608926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotadutide (50-300 µg, once-daily subcutaneous)
Number of subjects: 65
Study 31608926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 30672346 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Malay HA manual
Number of subjects: 90
Study 30672346 — intervention group
Group type: COMPARATOR
Intervention: Translated Malay HA manual
Number of subjects: 90
Study 28510573 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 398
Study 28510573 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 398
Study 28510573 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine + Primaquine (CQ+PQ)
Number of subjects: 398
Study 28510573 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine + Primaquine (AL+PQ)
Number of subjects: 398
Study 26863738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloferon
Number of subjects: 6034
Study 26863738 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3
Number of subjects: 6034
Study 26863738 — intervention group
Group type: COMPARATOR
Intervention: Etiotropic therapy with treatment and rehabilitation measures
Number of subjects: 6034
Study 26863738 — intervention group
Group type: COMPARATOR
Intervention: Etiotropic therapy alone
Number of subjects: 6034
Study 23625101 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE program (educational-behavioral parent intervention in the NICU)
Number of subjects: 253
Study 23625101 — intervention group
Group type: COMPARATOR
Intervention: Control group (mothers over 21 years old)
Number of subjects: 253
Study 20573162 — intervention group
Group type: EXPERIMENTAL
Intervention: YSPSL (rPSGL-Ig)
Number of subjects: 59
Study 20573162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 19852829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 242
Study 19852829 — intervention group
Group type: COMPARATOR
Intervention: Weekly chloroquine
Number of subjects: 242
Study 16899213 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help based on cognitive behaviour therapy with Internet support
Number of subjects: 73
Study 16899213 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 73
Study 15364311 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurazone-coated catheters
Number of subjects: 0
Study 15364311 — intervention group
Group type: COMPARATOR
Intervention: Standard silicone urinary catheters
Number of subjects: 0
Study 11512247 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine 5%
Number of subjects: 30
Study 11512247 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 10%
Number of subjects: 30
Study 9766455 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-SX group
Number of subjects: 16
Study 9766455 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 7819357 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermicidal contraception (Nonoxynol-9)
Number of subjects: 179
Study 7819357 — intervention group
Group type: COMPARATOR
Intervention: Non-spermicidal contraception
Number of subjects: 179
Study 3046630 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (30 to 90 mg bid)
Number of subjects: 295
Study 3046630 — intervention group
Group type: COMPARATOR
Intervention: Captopril (12.5 to 50 mg bid)
Number of subjects: 295
Study 31096815 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes (GDM)
Number of subjects: 614
Study 30009672 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional-printed wrist orthosis
Number of subjects: 22
Study 30009672 — intervention group
Group type: COMPARATOR
Intervention: Cock-up orthosis
Number of subjects: 22
Study 27790809 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 1.8 mg once daily for 24 weeks
Number of subjects: 241
Study 27790809 — intervention group
Group type: COMPARATOR
Intervention: placebo for 24 weeks
Number of subjects: 241
Study 27790809 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 1.8 mg once daily
Number of subjects: 241
Study 27790809 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 241
Study 26231755 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer benchmarked patient-reported outcome measures (PROMs) feedback and education
Number of subjects: 550
Study 26231755 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 550
Study 23623012 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol capsules (2.0 g/d)
Number of subjects: 41
Study 23623012 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (placebo)
Number of subjects: 41
Study 21324289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ion-exchange water softener plus usual eczema care (group A)
Number of subjects: 336
Study 21324289 — intervention group
Group type: COMPARATOR
Intervention: Usual eczema care alone (group B)
Number of subjects: 336
Study 21324289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ion-exchange water softener (group A)
Number of subjects: 336
Study 18795253 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) at ≤1.4 microg kg(‐1) h(‐1); n = 41
Number of subjects: 85
Study 18795253 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC, either propofol or midazolam); n = 44
Number of subjects: 85
Study 18795253 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 85
Study 17085157 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg (single doses)
Number of subjects: 16
Study 17085157 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg + Tamsulosin 0.4 mg (once daily for up to 14 days)
Number of subjects: 16
Study 17085157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17085157 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg + Tamsulosin 0.4 mg
Number of subjects: 16
Study 17085157 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg
Number of subjects: 16
Study 15248191 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (doses of 120, 180, 360, or 540 mg)
Number of subjects: 0
Study 15248191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15248191 — intervention group
Group type: EXPERIMENTAL
Intervention: Population spline model
Number of subjects: 0
Study 15248191 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparse data (66% randomly removed from placebo and active phases)
Number of subjects: 0
Study 11483144 — intervention group
Group type: EXPERIMENTAL
Intervention: Adderall (mixed amphetamine salts compound) at an average oral dose of 54 mg (administered in 2 daily doses)
Number of subjects: 27
Study 11483144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 9710010 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ALS
Number of subjects: 8
Study 9710010 — intervention group
Group type: COMPARATOR
Intervention: Control group A (other neurologic or muscular diseases)
Number of subjects: 8
Study 9710010 — intervention group
Group type: COMPARATOR
Intervention: Control group B (without neurologic disorders)
Number of subjects: 8
Study 7821320 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (2 mg.kg‐1 intravenous bolus in 10 min)
Number of subjects: 21
Study 7821320 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide (8 micrograms.kg‐1 maximum intravenous bolus in 15 min)
Number of subjects: 21
Study 7821320 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 21
Study 7821320 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 21
Study 2837895 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium viscosity solid or liquid guar gum
Number of subjects: 50
Study 2837895 — intervention group
Group type: EXPERIMENTAL
Intervention: High viscosity liquid guar gum
Number of subjects: 50
Study 2837895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31462812 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 2 μg/kg
Number of subjects: 120
Study 31462812 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 3 μg/kg
Number of subjects: 120
Study 31462812 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 4 μg/kg
Number of subjects: 120
Study 29415837 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/SOY
Number of subjects: 49
Study 29415837 — intervention group
Group type: COMPARATOR
Intervention: SMOF
Number of subjects: 49
Study 25521460 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment applied twice weekly
Number of subjects: 35
Study 25521460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 23388554 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based messages
Number of subjects: 139
Study 23388554 — intervention group
Group type: COMPARATOR
Intervention: Text-based messages
Number of subjects: 139
Study 21505316 — intervention group
Group type: EXPERIMENTAL
Intervention: VivaGel
Number of subjects: 61
Study 21505316 — intervention group
Group type: COMPARATOR
Intervention: VivaGel placebo
Number of subjects: 61
Study 21505316 — intervention group
Group type: COMPARATOR
Intervention: HEC placebo
Number of subjects: 61
Study 21505316 — intervention group
Group type: EXPERIMENTAL
Intervention: VivaGel and VivaGel placebo
Number of subjects: 61
Study 19339966 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnenolone (fixed escalating doses to 500 mg/day)
Number of subjects: 21
Study 19339966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 19339966 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnenolone
Number of subjects: 21
Study 19339966 — intervention group
Group type: COMPARATOR
Intervention: Pregnenolone and Placebo
Number of subjects: 21
Study 16940442 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel (100 mg daily) + Depomedroxyprogesterone acetate (DMPA, 300 mg/3 months)
Number of subjects: 44
Study 16940442 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel (100 mg daily) + Depomedroxyprogesterone acetate (DMPA, 300 mg/3 months) + Acyline (300 microg/kg every 2 weeks for 12 weeks)
Number of subjects: 44
Study 15311723 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 10
Study 10687811 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative research model implementation
Number of subjects: 0
Study 9198088 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation (ES) at 15 mA, 200 microseconds, with varying frequencies (0.1, 0.2, 0.3, 0.5, and 1 Hz)
Number of subjects: 13
Study 8238182 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 283
Study 4036786 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 23
Study 4036786 — intervention group
Group type: COMPARATOR
Intervention: Renografin‐76 (sodium meglumine diatrizoate)
Number of subjects: 23
Study 30346618 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipping
Number of subjects: 327
Study 30346618 — intervention group
Group type: COMPARATOR
Intervention: Coiling
Number of subjects: 327
Study 29532059 — intervention group
Group type: EXPERIMENTAL
Intervention: LINK LA Peer Navigation intervention
Number of subjects: 356
Study 29532059 — intervention group
Group type: COMPARATOR
Intervention: Transitional case management (control)
Number of subjects: 356
Study 26150057 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine combined with cognitive‐behavioral therapy
Number of subjects: 99
Study 26150057 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine combined with cognitive‐behavioral therapy and virtual reality exposure
Number of subjects: 99
Study 26150057 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine only
Number of subjects: 99
Study 24925090 — intervention group
Group type: COMPARATOR
Intervention: 200 mg entacapone
Number of subjects: 80
Study 24925090 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg opicapone
Number of subjects: 80
Study 24925090 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg opicapone
Number of subjects: 80
Study 24925090 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg opicapone
Number of subjects: 80
Study 24925090 — intervention group
Group type: COMPARATOR
Intervention: entacapone
Number of subjects: 80
Study 24925090 — intervention group
Group type: EXPERIMENTAL
Intervention: opicapone
Number of subjects: 80
Study 24925090 — intervention group
Group type: EXPERIMENTAL
Intervention: all active treatments
Number of subjects: 80
Study 23862255 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain bupivacaine 10 mg with 25 mcg of fentanyl
Number of subjects: 60
Study 23862255 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine 10 mg with 25 mcg of fentanyl
Number of subjects: 60
Study 19166763 — intervention group
Group type: EXPERIMENTAL
Intervention: Apexum procedure
Number of subjects: 48
Study 19166763 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 48
Study 17181461 — intervention group
Group type: EXPERIMENTAL
Intervention: Social marketing campaign intervention over 12 weeks at experimental sites.
Number of subjects: 4
Study 17181461 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention) at control sites.
Number of subjects: 4
Study 15893158 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 US dollars cash incentive
Number of subjects: 0
Study 15893158 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 US dollars cash incentive
Number of subjects: 0
Study 15893158 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 US dollars cash incentive
Number of subjects: 0
Study 15893158 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 US dollars gift certificate
Number of subjects: 0
Study 15893158 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 US dollars gift certificate
Number of subjects: 0
Study 15893158 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 US dollars gift certificate
Number of subjects: 0
Study 15893158 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher payments (cash or gift certificate)
Number of subjects: 0
Study 15893158 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher magnitude payments
Number of subjects: 0
Study 12485511 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea disintegrating buccal tablet (DBT) 0.1 mg before chemotherapy
Number of subjects: 73
Study 12485511 — intervention group
Group type: COMPARATOR
Intervention: Kytril tablet 2 mg after chemotherapy
Number of subjects: 73
Study 9802273 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (nitrendipine 10-40 mg/day, possibly with enalapril 5-20 mg/day, hydrochlorothiazide 12.5-25 mg/day)
Number of subjects: 2418
Study 9802273 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 2418
Study 9802273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2418
Study 7895926 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (1 g twice daily)
Number of subjects: 50
Study 7895926 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg twice daily)
Number of subjects: 50
Study 7895926 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg twice daily for 14 days, then 20 mg once in the morning for 28 days)
Number of subjects: 50
Study 2013669 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 4 mg by mouth
Number of subjects: 18
Study 2013669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6335005 — intervention group
Group type: EXPERIMENTAL
Intervention: Functioning TENS units
Number of subjects: 31
Study 6335005 — intervention group
Group type: COMPARATOR
Intervention: Non-functioning TENS units
Number of subjects: 31
Study 30500110 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox Max (magnesium and aluminum hydroxides plus simethicone)
Number of subjects: 15
Study 30500110 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 15
Study 30500110 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 15
Study 30500110 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxy saxagliptin
Number of subjects: 15
Study 29119718 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone treatment (15 mg/d)
Number of subjects: 13
Study 29119718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 27960026 — intervention group
Group type: EXPERIMENTAL
Intervention: NTVC (Topical vasodilating cream)
Number of subjects: 81
Study 27960026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 24691252 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (60-70% peak oxygen uptake [VO2peak] for 45 min, 3 days/week)
Number of subjects: 34
Study 24691252 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 34
Study 22658450 — intervention group
Group type: EXPERIMENTAL
Intervention: Jubilee dressing method
Number of subjects: 124
Study 22658450 — intervention group
Group type: COMPARATOR
Intervention: Standard adhesive dressing
Number of subjects: 124
Study 20683462 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice-ORS
Number of subjects: 30
Study 20683462 — intervention group
Group type: COMPARATOR
Intervention: Glucose-ORS
Number of subjects: 30
Study 20683462 — intervention group
Group type: COMPARATOR
Intervention: Glucose-ORS plus ARS
Number of subjects: 30
Study 18338627 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Chinese materia medica (b. i. d)
Number of subjects: 31
Study 18338627 — intervention group
Group type: COMPARATOR
Intervention: Oral carboxymethyl liquor (control)
Number of subjects: 31